InSprint StoriesbyRoshni BiswasTackling a Cancer Immunology Research Challenge with a Design SprintRoundup of how a Cancer Genomics Research Team conducted the Design Sprint!Apr 3, 2020
Adam PennycuickImmuno-oncology: what’s next?In 2018, Jim Allison and Tasuku Honjo won the Nobel prize in medicine for their work developing immune checkpoint inhibitors. These drugs…Dec 23, 2022Dec 23, 2022
Pheast TherapeuticsUnveiling Pheast Therapeutics, an immuno-oncology company that is activating the immune system to…By Amira Barkal, MD, PhD, Principal Founder and Interim CEOApr 26, 2022Apr 26, 2022
TTP — The Technology PartnershipBeyond intravenous delivery: choosing better administration routes for oncologic drugsIntravenous delivery remains the dominant paradigm in oncology, but even with precision medicine few drugs pass late stage clinical trials…May 13, 2019May 13, 2019
InSprint StoriesbyRoshni BiswasTackling a Cancer Immunology Research Challenge with a Design SprintRoundup of how a Cancer Genomics Research Team conducted the Design Sprint!Apr 3, 2020
Adam PennycuickImmuno-oncology: what’s next?In 2018, Jim Allison and Tasuku Honjo won the Nobel prize in medicine for their work developing immune checkpoint inhibitors. These drugs…Dec 23, 2022
Pheast TherapeuticsUnveiling Pheast Therapeutics, an immuno-oncology company that is activating the immune system to…By Amira Barkal, MD, PhD, Principal Founder and Interim CEOApr 26, 2022
TTP — The Technology PartnershipBeyond intravenous delivery: choosing better administration routes for oncologic drugsIntravenous delivery remains the dominant paradigm in oncology, but even with precision medicine few drugs pass late stage clinical trials…May 13, 2019
